Studying IBI351 plus Cetuximab beta for a type of lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two targeted drugs, IBI351 and Cetuximab beta, for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and hasn't been treated yet. The goal is to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lung cancer called non-small cell lung cancer that has spread or cannot be removed by surgery.
- A test must show your cancer has a specific mutation called KRAS G12C.
- You should be between 18 and 75 years old.
- You must be healthy enough to be up and about (ECOG score 0 or 1).
- You should not have had any previous cancer treatment for advanced disease, though past adjuvant therapy is allowed if the cancer came back more than 6 months later.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with advanced or spreading non-small cell lung cancer that has a KRAS G12C mutation, who have already taken the drug IBI-351. It aims to understand how well this drug works in everyday practice and why it might help you.
This trial tests a new combination of two targeted medicines for advanced non-small cell lung cancer with a specific gene change (KRAS G12C). The goal is to see if this combination can shrink or slow the cancer.
This trial tests a new drug called IBI3005, given with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It may help shrink tumors or slow their growth.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
This trial tests a new drug called BEBT-109 for people with a specific type of non-small cell lung cancer that has an EGFR exon 20 insertion mutation. It's for those who haven't had prior treatment for advanced or metastatic lung cancer, and it aims to see if the drug can help shrink or control the cancer.
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.